Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
06. Januar 2022 08:30 ET
|
Vaxcyte, Inc.
-- Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide...
Vaxcyte to Present at Upcoming Investor Conferences
11. November 2021 16:05 ET
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
10. November 2021 16:10 ET
|
Vaxcyte, Inc.
-- Company Expects to Submit VAX-24 IND Application to FDA in Q1 2022 -- -- Completed Manufacture of VAX-24 GMP Drug Product and GLP Toxicology Study -- FOSTER CITY, Calif., Nov. 10, 2021 (GLOBE...
Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors
28. Oktober 2021 08:30 ET
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference
28. September 2021 16:05 ET
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference
21. September 2021 16:01 ET
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors
20. September 2021 16:30 ET
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update
11. August 2021 16:07 ET
|
Vaxcyte, Inc.
FOSTER CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...
Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections
05. August 2021 08:30 ET
|
Vaxcyte, Inc.
-- Award Commits an Additional $3.2 Million in Funding; Total Potential Funding of $29.7 Million Based on Future Milestones -- -- Vaxcyte Plans to Initiate IND-Enabling Studies for VAX-A1 in Second...
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
27. Mai 2021 16:05 ET
|
Vaxcyte, Inc.
FOSTER CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines...